A Protocol To Monitor From Birth To Age 15 Months The Neurological Development Of Infants With Exposure In-utero In Tanezumab Clinical Studies At All Investigational Sites

Trial Profile

A Protocol To Monitor From Birth To Age 15 Months The Neurological Development Of Infants With Exposure In-utero In Tanezumab Clinical Studies At All Investigational Sites

Recruiting
Phase of Trial: Phase III

Latest Information Update: 16 May 2018

At a glance

  • Drugs Tanezumab (Primary)
  • Indications Back pain; Cancer pain
  • Focus Adverse reactions
  • Sponsors Pfizer
  • Most Recent Events

    • 07 May 2018 Planned End Date changed from 10 Jul 2020 to 1 Apr 2022.
    • 07 May 2018 Planned primary completion date changed from 12 Jan 2020 to 1 Apr 2022.
    • 19 Dec 2017 Planned End Date changed from 1 Jul 2020 to 10 Jul 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top